- Home
- VINP vs HQL Comparison
VINP vs HQL Comparison
Compare VINP & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | VINP | HQL |
|---|---|---|
| Founded | 2009 | 1992 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Investment Managers |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 638.8M | 585.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | VINP | HQL |
|---|---|---|
| Price | $9.79 | $20.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | 62.3K | ★ 138.4K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | 5.72% | ★ 11.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | N/A | N/A |
| Revenue This Year | $18.07 | N/A |
| Revenue Next Year | $12.74 | N/A |
| P/E Ratio | ★ $24.41 | $26.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.20 | $12.87 |
| 52 Week High | $13.61 | $20.68 |
Technical Indicators
Market Signals| Indicator | VINP | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 40.65 | 75.95 |
| Support Level | $9.61 | $16.51 |
| Resistance Level | $10.24 | N/A |
| Average True Range (ATR) | 0.37 | 0.39 |
| MACD | 0.02 | 0.20 |
| Stochastic Oscillator | 13.14 | 86.61 |
Price Performance
Historical ComparisonAbout VINP Vinci Partners Investments Ltd.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.